Navigation Links
AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
Date:11/19/2009

hold. This is exactly what we did with our Alzheimer's vaccination program and the outcome in the Phase I trials at this stage enabled us to make this decision earlier than we expected and to offer a booster vaccination to the AD02-treated patients. Finally, we can also redirect our resources which will now be available for our other vaccination programs." AFFiRiS AG can also invest all of the EUR 10 million, paid by licensing partner GSK Biologicals as a milestone payment for the positive completion of the Phase I studies, in the other R&D programs.

The vaccine development program of AFFiRiS is based on the company's AFFITOME(R) technology, which also delivered the vaccines tested so far. Also based on this technology are six other vaccination programs being developed by AFFiRiS AG, which target, among other indications, Parkinson's disease and atherosclerosis.

About AFFiRiS AG (status November 2009):

Based on proprietary patent positions, AFFiRiS has developed tailored peptide vaccines against Alzheimer's Disease, Parkinson's and four other diseases characterized by urgent medical requirement and attractive market volumes. Alzheimer's is the current lead indication and clinical Phase I trials have just been completed on two product candidates. AFFiRiS succeeded in attracting GlaxoSmithKline Biologicals as its licensing partner in October 2008. The contract contains provisions for (milestone-dependent) payments of up to EUR 430 million. Based on the successful completion of two clinical Phase I trials, a payment of EUR 10 million was made in October. AFFiRiS currently employs 60 highly-qualified staff at its premises on the St. Marx Campus in Vienna, Austria (http://www.affiris.com).


    Contact AFFiRiS AG:
    Mag. Agnes Meyer
    Karl-Farkas-Gasse 22
    T +43-1-798-15-75-3
    mailto:agnes.meyer@affiris.com
    '/>"/>
SOURCE AFFiRiS AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
2. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
3. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
4. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
5. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
6. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
7. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009
8. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
9. Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
10. Bavarian Nordic A/S - Half Year Interim Report 2009
11. Arpida Reports Interim Results For Six Months to 30 June 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014   Synthetic Biologics, Inc. ... novel anti-infective biologic and drug programs targeting specific ... today that its novel C. difficile ... th Interscience Conference on Antimicrobial Agents and ... D.C. Synthetic Biologics, Senior ...
(Date:8/19/2014)... August 19, 2014 Sales Horizons, a ... its online sales skills training course to ... , MedTech clinical staff spend the majority of their ... standalone medical center, or physician practice – providing support ... why stop there? Sales Horizons believes clinical staff are ...
(Date:8/18/2014)... (Aug. 18, 2014) -- A new therapy developed ... (USF) Morsani College of Medicine and Columbia University ... complications of interventional cardiovascular disease treatment. , ... the novel molecular therapy could selectively inhibit blood ... a medical procedure using a balloon catheter to ...
(Date:8/18/2014)... Md. , Aug. 18, 2014 /PRNewswire/ ... maker of advanced consumer medical devices said ... was interviewed by CEOLIVE.TV as part ... The entire interview is available at ... Dr. Kotak explains to investors the unique ...
Breaking Biology Technology:Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3
... speculate that the Greater Madison area, while a key ... the "critical mass" of talent, innovation, and specialization necessary ... sustained growth. , ,But as area biotech leaders and ... discovery tool provider, Caden Biosciences , to a ...
... Madison, Wis. - The Madison-based Imago Scientific ... to Iowa State University's College of Engineering ... High Throughput Atom-Scale Analysis. , ,The lab will be ... Discovery, which is led by Balaji Narasimhan, an associate ...
... to the future growth and success of the state ... state boasts significant competitive advantages in terms of talent, ... mass needed to compete with our most significant competition ... resources so vital to building and sustaining economic growth. ...
Cached Biology Technology:Caden Biosciences may signal critical mass 2Regional collaboration is key to state's future 2Regional collaboration is key to state's future 3
(Date:8/20/2014)... approximately 3 million infants, a team of scientists across ... Massachusetts Medical School, have shown that newborn screening for ... public health newborn screening programs. Data from 11 newborn ... the Journal of the American Medical Association ... newborns is higher than previously thought and believed to ...
(Date:8/20/2014)... scientists have discovered that acral melanomas the rare type ... are genetically distinct from other more common types of ... in the journal Pigment Cell & Melanoma Research . ... hands, soles of the feet, nail-beds and other hairless parts ... it,s not caused by UV damage from the sun. , ...
(Date:8/20/2014)... pepper causes a burning spiciness that is irresistible to ... pepper,s effect are using their findings to develop a ... can be caused by inflammation or other problems. They ... tested in clinical trials, in ACS, Journal of ... that decades ago, scientists had pegged a compound called ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... U.S. Department of Energy this month awarded a group ... develop bacteria that can turn the methane in natural ... we,re shooting for will have the same fuel characteristics ... professor of chemical engineering and microbiology. "It can be ...
... Innes Centre will publish the first RNA sequence data on the ... will release the data via a website to a system designed ... used to crowdsource expertise during the 2011 E. coli ... able to access the RNA sequence and start to analyse it ...
... University of Illinois at Urbana-Champaign has received a fiveyear, $5.7 ... in corn. These strains have the potential to combat the ... yield. A team at the Institute for Genomic Biology in ... lead the research. "Ozone can cause major damage ...
Cached Biology News:Energy Deptartment funds UW project to turn wasted natural gas into diesel 2Crowdsourcing to kickstart comeback from ash dieback 2University of Illinois receives grant to study ozone resistance in corn 2
Assay Diluent, 10 L...
Assay Diluent Trial Pack, 4 x 100 mL...
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
SpectroQuest single beam 1.8nm UV/Vis spectrophotometer; stand-alone unit...
Biology Products: